A study of JNJ-77242113 in participants with moderate-to-severe plaque psoriasis

Phase 2

• Conditions: Plaque psoriasis; Skin and Connective Tissue Diseases; Psoriasis vulgaris

• Registration Number: ISRCTN76915275
• Lead Sponsor: Janssen (Belgium)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2022-05-10
• Last Update Posted: 20 June 2022
• Study Completion: 2023-02-24

Recruitment & Eligibility

• Status: Ongoing
• Sex: All
• Target Recruitment: 240

Inclusion Criteria

1. Participant has a diagnosis of plaque psoriasis, with or without psoriatic arthritis (PsA), for at least 6 months prior to the first administration of study intervention
2. Participant is a candidate for phototherapy or systemic treatment for plaque psoriasis
3. Participant has a total body surface area (BSA) greater than or equal to (=) 10 percent (%) at screening and baseline
4. Participant has a total Psoriasis area and severity index (PASI) =12 at screening and baseline
5. Participant has a total Investigator global assessment (IGA) =3 at screening and baseline

Exclusion Criteria

1. Participant has a nonplaque form of psoriasis (for example, erythrodermic, guttate, or pustular)
2. Participant has current drug-induced psoriasis (for example, a new onset of psoriasis or an exacerbation of psoriasis from beta-blockers, calcium channel blockers, or lithium)
3. Participant have previously received any other therapeutic agent directly targeted to interleukin 23 receptor (IL-23R) (including but not limited to guselkumab, tildrakizumab, or risankizumab)
4. Participant has received any therapeutic agent directly targeted to interleukin 17 receptor (IL-17) or interleukin 12/23 receptor (IL-12/23) (including but not limited to secukinumab, ixekizumab, brodalumab, or ustekinumab) or has received anti-tumor necrosis factor [TNF]-alpha biologic therapy (including, but not limited to adalimumab) within 12 weeks or 5 half-lives, whichever is longer, of the first administration of study intervention
5. Participant has received agents that deplete B cells (including, but not limited to, rituximab, or alemtuzumab) within 26 weeks of the first administration of study intervention

Study & Design

• Study Type: Interventional
• Study Design: Not specified